Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Rectal IW-3300 in Healthy Subjects
NCT05362695Phase 1Completed
- Sponsor
- Ironwood Pharmaceuticals
- Start
- May 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IW-3300 in interstitial cystitis (IC), bladder pain syndrome (BPS) and endometriosis (6 cohorts), sponsored by Ironwood Pharmaceuticals. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Number of Participants With Serious TEAEs. Started May 2022; status: completed.
02
Drugs
IW-3300
03
Conditions
interstitial cystitis (IC)bladder pain syndrome (BPS)endometriosis
Beyond the preview
Go deeper on NCT05362695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362695.